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Background. Clinical trials in cancer frequently include
cancer-specific measures of health but not preference-
based measures such as the EQ-5D that are suitable for
economic evaluation. Mapping functions have been devel-
oped to predict EQ-5D values from these measures, but
there is considerable uncertainty about the most appropri-
ate model to use, and many existing models are poor at
predicting EQ-5D values. This study aims to investigate
a range of potential models to develop mapping functions
from 2 widely used cancer-specific measures (FACT-G and
EORTC-QLQ-C30) and to identify the best model. Methods.
Mapping models are fitted to predict EQ-5D-3L values using
ordinary least squares (OLS), tobit, 2-part models, splining,
and to EQ-5D item-level responses using response mapping
from the FACT-G and QLQ-C30. A variety of model specifi-
cations are estimated. Model performance and predictive
ability are compared. Analysis is based on 530 patients
with various cancers for the FACT-G and 771 patients
with multiple myeloma, breast cancer, and lung cancer for
the QLQ-C30. Results. For FACT-G, OLS models most accu-
rately predict mean EQ-5D values with the best predicting
model using FACT-G items with similar results using tobit.
Response mapping has low predictive ability. In contrast,
for the QLQ-C30, response mapping has the most accurate
predictions using QLQ-C30 dimensions. The QLQ-C30 has
better predicted EQ-5D values across the range of possible
values; however, few respondents in the FACT-G data set
have low EQ-5D values, which reduces the accuracy at the
severe end. Conclusions. OLS and tobit mapping func-
tions perform well for both instruments. Response map-
ping gives the best model predictions for QLQ-C30. The
generalizability of the FACT-G mapping function is lim-
ited to populations in moderate to good health. Key
words: health-related quality of life; mapping functions;
cancer; EQ-5D-3L; FACT-G; EORTC-QLQ-C30. (Med
Decis Making 2015;35:912–926)
INTRODUCTION
In the United Kingdom, the National Institute for
Health and Care Excellence (NICE) recommend the
EQ-5D to measure preference-based health-related
quality of life (HRQL) to estimate quality-adjusted
life years (QALYs) in economic evaluations.1 It has
been demonstrated that the EQ-5D-3L is sensitive to
changes in HRQL in patients with cancer.2 However,
many cancer studies do not include the EQ-5D and
are more likely to include 1 of 2 cancer-specific
HRQL questionnaires: the European Organization
for Research and Treatment Quality of Life Question-
naire Core 30 (EORTC QLQ-C30) or the Functional
Assessment of Cancer Therapy—General Scale
(FACT-G), both of which are non-preference-based
measures. NICE guidelines acknowledge that the
EQ-5D is not always available and in these situations
recommend using mapping to estimate EQ-5D. Map-
ping allows health state utility values to be predicted
when no preference-basedmeasure is included in the
study. This approach involves estimating the relation-
ship between a non-preference-based measure and
a generic preference-based measure using statistical
association, and it requires a degree of overlap between
thedescriptive systems of the 2measures and that the 2
measures are administered on the same population. A
review of mapping functions by Brazier et al.3
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demonstrates that researchers use a number of models,
including ordinary least squares regression (OLS), gen-
eralized linear models, tobit, censored absolute devi-
ance (CLAD), 2-part models, and response mapping,
to predict health state preference values. Studies also
report a variety of methods to assessmodel and predic-
tive performance, including predicted mean and stan-
dard deviation, median, range of predictions, Akaike
information criteria (AIC), Bayes information criteria
(BIC), R2, pseudo-R2, mean estimates across severity
groups, root mean square error (RMSE), mean square
error (MSE), and mean absolute error (MAE).
Only 1 mapping function has been published that
maps from FACT-G to EQ-5D-3L: it fits separate OLS
and CLAD models at the FACT-G dimension level,
and shows that values are poorly predicted for high
and low EQ-5D values.4 There are several published
mapping functions for the EORTC QLQ-C30. Poten-
tially, the most useful function is that of McKenzie
and van der Pol,5 who used OLS to predict EQ-5D-
3L values and ordered probit to predict EQ-5D-3L
dimension levels. The ordered probit model did not
produce reliable predictions, but the OLS gave rea-
sonable EQ-5D-3L estimates. It is possible that other
mapping functions such as the tobit model would
produce more accurate estimates, although these are
not explored in this article. Recently, Khan and Mor-
ris6 explored a number of alternative models for pre-
dicting EQ-5D in patients with lung cancer; their
models assume EQ-5D scores lie between 0 and 1,
and they show that the nonlinear beta-binomialmodel
gave the best predictions of EQ-5D. The beta-binomial
model is not going to be applicable to all populations
because some respondents will have negative EQ-5D
scores. Proskorovsky et al.7 used linear regression to
predict EQ-5D-5L using a sample of 154 patients
with multiple myeloma and to estimate models with
and without the EORTC QLQ-MY20; this is used in
conjunction with the EORTC QLQ-C30 to assess qual-
ity of life in patients with multiple myeloma, but the
results are not validated using an external sample.
The remaining published mapping functions are not
as useful. Kontodimopoulous et al.8 used OLS to pre-
dict EQ-5D-3L; the model is based on a small sample
of patients, and they state that their function is unreli-
able. Wu et al.9 required data on FACT-G as well as
EORTC QLQ-C30 to produce mapping estimates,
which studiesmaynot routinely collect together. Pick-
ard et al.10 mapped to patient time trade-off (TTO) val-
ues rather than the EQ-5D-3L index. Crott and Briggs11
developed their function from a female-only sample,
and therefore the results are not generalizable, as evi-
dent by results from assessment of this mapping func-
tion12 that demonstrate that EQ-5D-3L estimates are
not stable among different data sets. Versteegh
et al.13 only used OLS in their analysis and only pro-
vided Dutch values, not UK ones; whereas Versteegh
et al.14 developed separate mapping functions for
those in poor health versus those in better health,
and these have limited reliability due to small sample
sizes at the poor health end. Some of these mapping
functions have worse predictive performance than
the McKenzie and van der Pol5 model in a multiple
myeloma patient data set.15 There are other papers
that map to non-UK values of the EQ-5D-3L.16–18
Given the lack of robust mapping studies in this
area, the aim of this article is to estimate mapping
functions from 2 cancer-specific HRQL measures,
FACT G and EORTC QLQ-C30, to the EQ-5D-3L to
test the applicability of different mapping approaches
that have been used in the literature and provide rec-
ommendations for future mapping studies. This arti-
cle presents the results from testing alternative
common modeling techniques that are recommended
in the literature and uses recommended criteria to
identify the most appropriate mapping functions.
EQ-5D-3L is referred to as EQ-5D andEORTCQLQ-
C30 as QLQ-C30 in the rest of the article.
METHODS
Measures
EQ-5D
The EQ-5D is the most widely used generic
preference-based measure of health-related quality of
Received 8 August 2014 from School of Health and Related Research
(ScHARR), University of Sheffield, Sheffield, UK (TAY, CM, DR, JEB)
and HERG, Brunel University, Uxbridge, Middlesex, UK (LL). This
work has been presented at the following meetings: International Soci-
ety of Quality of Life Research (ISOQOL), Budapest, Hungary, October
2012; Health Economic Study Group (HESG), Exeter, UK, January
2013; 9th World Congress on Health Economics (iHEA), Sydney, Aus-
tralia, July 2013; and Centre for Research in Health and Economics
(CRES), Economics and Business Department, Pompeu Fabra Univer-
sity, Barcelona, Spain, June 2014. Financial support for this study was
provided entirely by a grant from the MRC-NIHR (Medical Research
Council and National Institute for Health Research) Methodology
Research Programme. The funding agreement ensured the authors’
independence in designing the study, interpreting the data, writing,
and publishing the report. Revision accepted for publication 13 April
2015.
Address correspondence to Dr. Tracey Young, School of Health and
Related Research, University of Sheffield, Regent Court, 30 Regent
Street, Sheffield, S1 4DA, UK; tel.: +44 114 2220837; fax: +44 114
2724095; e-mail: t.a.young@sheffield.ac.uk.
MAPPING FUNCTIONS IN HEALTH-RELATED QUALITY OF LIFE
ORIGINAL ARTICLE 913
life. The EQ-5D has 5 dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depres-
sion.19 Each dimension has 3 levels of severity. Each
health state described by the EQ-5D has a utility value
anchored on a 0 to 1 scale, where 0 represents death
and 1 represents full health. The values used here are
produced using the UK value set.20
FACT-G
The FACT-G is a 27-item cancer-specific HRQL
measure that has been widely validated.21 Each
item has 5 options ranging from not at all (a score of
0) to very much (a score of 4), and these are summed
to obtain a global score as well as 4 subscale scores:
physical well-being, social/family well-being, emo-
tional well-being, and functional well-being.
EORTC QLQ-C30
The QLQ-C30 is a 30-item cancer-specific HRQL
measure that has also been widely validated.22 Two
items ask about overall quality of life and overall
health, and the remainder cover 5 functioning scales
(physical, role, social, emotional, and cognitive func-
tioning) and 9 symptoms scales (fatigue, nausea and
vomiting, pain, dyspnea, sleep disturbance, appetite
loss, constipation, diarrhea, and financial impact).
Data
Four data sets are used in this analysis: One con-
tains the FACT-G and EQ-5D, and the remaining three
contain the QLQ-C30 and EQ-5D and are combined to
produce a reliable mapping function. The FACT-G
data set consists of 530 US respondents with 13 differ-
ent types of stage III and IV cancerswho completed the
EQ-5D and FACT-G.23 Fifty-two percent of respond-
ents are male, and the average age of the sample is 59
years. The 3 data sets combined for the QLQ-C30map-
ping analysis are a randomized controlled trial of 572
patients with multiple myeloma (VISTA study; Clini-
calTrials.gov number NCT00111319),24 and 100
patients with breast cancer and 99 patients with lung
cancer having consultations at a Canadian cancer
clinic (VancouverCancerClinicdata). This gives a total
of 771 cases for the mapping study; 44% of responders
are male, and the mean age of patients is 68 years.
Analysis
Models
Five commonly applied alternative types of model
are fitted to the data: OLS, tobit, 2-part models, and
splining to map to EQ-5D values, and response map-
ping to map to individual EQ-5D dimension scores.
The most commonly used mapping model reported
in the literature is OLS.25,26 These models are typi-
cally able to predict the mean values but are poor at
predicting those in poor health and full health, and
they do not allow for the fact that the EQ-5D is
bounded at 1 for full health and20.594 for the worst
possible state described by EQ-5D. Tobit models are
therefore fitted to allow for the bounded nature of
EQ-5D, thus limiting predictions to within a credible
range. An alternative model that can be fitted in an
attempt to predict responders in perfect health is
the 2-part model, which uses a combination of 2 dif-
ferentmodel types to predict different parts of the dis-
tribution of the data. Logistic regression is fitted to
predict the probabilty of whether responders are in
full health (FH), and a truncated OLS is applied to
predict EQ-5D values for those not in full health.
The results from the 2 parts of the model are com-
bined to obtain an overall value using an expected
value approach,27 that is,
Expected EQ  5Dð Þ5
Probability Full healthð Þ  EQ  5D in FHð Þð Þ
1 EQ  5D if not FH  1 Probility Full healthð Þð Þð Þ
Given that the EQ-5D fails to approximate to the nor-
mal distribution, the final model that is fitted to the
EQ-5D index uses splining, also known as fractional
polynomials. Splining can be used to identify
changes (cut points) in the distribution of the contin-
uous explanatory variables (QLQ-C30 or FACT-G
total or domain scores) and models these changes
using different mathematical functions. The cut
points were identified using the multivariable frac-
tional polynomial function in Stata.28 This function
identifies cut points and fits all possible polynomial
functions to the data using power functions ranging
from 22 to 3, and identifies the best-fitting model
for predicting the outcome variable (EQ-5D score).
Splining functions are applied to the best-fitting
OLS/tobit dimension based models to test whether
splines offered an improvement over using squared
terms.
In the mapping literature, OLS, tobit, 2-part, and
splining models are usually reliable at predicting
the group EQ-5D mean and median values, and they
are able to distinguish between severity levels but
are poor at predicting the overall range of EQ-5D
values. An alternative to modeling the EQ-5D value
is to use response mapping, which can predict the 5
EQ-5D dimension levels.29,30 Multinomial logistic
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regression models are estimated for each dimension,
and the estimates from these regressions are used to
categorize respondents into levels 1, 2, or 3 of each
of the EQ-5D dimensions and thus predict the EQ-
5D health state for each respondent. A total of 2000
Monte Carlo simulations are run to estimate EQ-5D
health states. The standard set of UK general popula-
tion values is then applied to each predicted health
state to obtain EQ-5D values.20
Eight model specifications (models 1 to 8) are fit-
ted for OLS, tobit, and 2-part models; these specifica-
tions can be seen in Table 2, illustrated using the
FACT-G data set. Model 1 uses the FACT overall
score. Models 2 to 5 are based on FACT-G domain
scores; model 2 includes all domains regardless of
statistical significance, model 3 includes only statis-
tically significant domains,model 4 includes squared
and square root terms, and model 5 includes interac-
tion terms. Models 6 and 7 are item-level models that
include only significant items; model 7 merges item
levels for levels that are shown to be disordered in
model 6 (item coefficent size does not increase or
decrease by item level). Patient anddisease character-
istics were explored in model 8. Splining models
were fitted to total score and domain level (models
1 to 5).
To avoid overfitting models, the rule of 10 partici-
pants per variable for continuous models and 10
events for the smallest category for response-
mapping models is used. The FACT-G data set does
not include responders with very poor health, with
only 0.9% of responders having negative EQ-5D val-
ues in contrast to 18% of responders reporting full
health on the EQ-5D.No responder had extreme prob-
lems for mobility, and few responders indicated
extreme problems for self-care (0.4%), usual activi-
ties (6%), pain/discomfort (3%), or anxiety/depres-
sion (2%). Applying the overfitting rule to the
response-mapping EQ-5D level 3 predictions for
models that would include FACT-G item levels
(models 6 and 7) restricted the number of items
that should be included to 1 item. A model that
could include only 1 FACT-G item is not going to
be useful at predicting EQ-5D dimension responses,
so model 6 and 7 are not fitted. There were a slightly
higher number of EQ-5D level 3 responders for the
QLQ-C30 data set, but we were again restricted to
including 1 QLQ-C30 item; again, we chose not to
include model 6. However, because there are more
EQ-5D level 3 responses, it was possible to collapse
QLQ-C30 items into a smaller number of levels.
Therefore, we were able to fit model 7 to the QLQ-
C30 data set.
Models are fitted using backward regression, and
variables are removed from the model if nonsignifi-
cant at p\ 0.1. When variables are highly correlated
(correlation . 0.7), the variable that is most signifi-
cant and judged most likely to map to the EQ-5D
based on prior expectations is selected. Standard
errors of regression coefficents are calculated from
bootstrap estimates with 5000 bootstrap samples for
each model.
Model goodness of fit is measured using AIC, BIC,
and MAE, in which smaller values indicate better
model fit. Model performance is also assessed visu-
ally by plotting observed and predicted EQ-5D val-
ues. Standard model tests are also examined,
including R2 and adjusted R2 for OLS and pseudo
R2 for the other models; the Ramsey Regression Equa-
tion Specification Error Test (RESET) is used in OLS
to test whether nonlinear conbinations of variables in
themodel help explain the variability, where a signif-
icant result indicates that a nonlinear model is more
appropriate. Sigma is reported for tobit and truncated
regression models, and is the equivalent to RMSE in
linear regression models. The link test is used to
check model specification. The Hosmer–Lemeshow
test is used to assess goodness of fit for logistic regres-
sion models (first part of 2-part models), which
assesses whether predicted probabilities agree with
observed probabilities and should be nonsignificant
for a model that accurately predicts observed values.
Model performance and discrimination
Summary statistics, including mean and range, are
examined to assess overall model predictions. A
severity measure is used to assess the discriminative
performance of the predicted EQ-5D value among dif-
ferent severity groups. For FACT-G, the Eastern
Cooperative Oncology Group (ECOG) performance
status31 is used to categorize respondents according
to severity. The ECOG has 5 response categories: nor-
mal activity without symptoms, some symptoms but
do not require bed rest during thewaking day, require
bed rest for less than 50% of the waking day, require
bed rest for more than 50% of the waking day, and
unable to get out of bed. There are no patients in the
most severe level, and few patients (n = 21 [4%])
required bed rest for more than 50% of the waking
day; therefore, this category is merged with do not
require bed rest less than 50% of the waking day.
The general health status item of the QLQ-C30
is used to categorize respondents according to
severity in the QLQ-C30 data set. Response options
ranged from poor to excellent (i.e., from 1 to 7). Dis-
criminative ability among severity groups using these
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measures is tested using ANOVA.MAEs are reported
for each subgroup.
Model validation
Models are validated internally using bootstrap-
ping techniques to estimate a shrinkage factor that
allows for overoptimism of the predictive ability of
the fitted model (a model is better at predicting esti-
mates on the same data from which the model is
derived, compared to an external data set). Methods
reported by Steyerberg et al.32 are used to assess all
models, and shrinkage coefficients are reported to
counter overoptimism of estimates. To estimate the
shrinkage factors, 5000 bootstrap estimates are run,
and for each bootstrap sample the EQ-5D predicted
score (linear prediction) is calculated. The slope of
the EQ-5D predicted score in relation to the observed
score is then calculated for each sample, and the
mean slope across the 5000 samples denotes the
shrinkage coefficient. A shrinkage coefficient of less
than 1 (the typical value expected for a shrinkage
coefficient) reflects an ‘‘overfitting’’ of the data.
Model selection
When producing amappingmodel, the factors that
are important in selecting a model are accuracy of the
predicted mean and standard error, the range of pre-
dictions, MAE, shrinkage, and the reproducibility of
the model among different severity states. Mapping
and model-fitting literature do not suggest a single
criterion for use in selecting the best-fitting model,
and the most appropriate measure may depend on
the purpose of the mapping function; for example,
populating a model may require accurate predictions
ofmean preference-based values for different severity
groups, whereas accurate overall means at different
time points may be sufficient when subgroup analy-
sis is not undertaken. Therefore, when selectingmod-
els, all criteria are given equal weighting, models are
ranked based on these factors, and the mean rank per
model is estimated. The model with the best ranking
is then selected, and these are then compared among
the different estimation methods (OLS, tobit, 2-part,
splining, and response mapping). All mapping func-
tions are fitted in STATA version 12.33
Financial support for this study was provided
entirely by a grant from the MRC-NIHR (UK Medical
Research Council and National Institute for Health
Research) Methodology Research Programme. The
study was part of the NICEQoL project looking at
the use of generic and condition-specific measures
of HRQL for NICE decision making.2 The funding
agreement ensured the authors’ independence in
designing the study, interpreting the data, writing,
and publishing the report.
RESULTS
Descriptive Statistics
FACT-G
The characteristics and a summary of EQ-5D val-
ues and FACT-G responses are presented in Table 1.
EQ-5D values did not cover the full possible range
and went from 20.135 to 1. The distribution of the
EQ-5D index for the FACT-G data set is shown in Fig-
ure 1a, which reflects the distribution of possible EQ-
5D values. The average global FACT-G score ranges
from 33 to 108; thus, like the EQ-5D, it did not cover
the worse end of the FACT-G scale. The relationship
between the global FACT-G score and EQ-5D is mod-
erate (Spearman’s correlation r = 0.575). The EQ-5D
correlates moderately with the physical and func-
tional domains of the FACT-G (r = 0.566, r = 0.501,
respectively), although the correlations are weak for
the social and emotional domains (r = 0.178, r =
0.382, respectively).
QLQ-C30
The characteristics and a summary of EQ-5D val-
ues and QLQ-C30 responses are presented in Table
1 for the combined sample and for each data set.
Mean age and gender distribution varied by data set,
as did mean EQ-5D values, which are lowest for the
multiple myeloma data set. Only the multiple mye-
loma data set covered the entire range of the EQ-5D,
and it has lower ceiling effects than the other data
sets, with 8% of responses at full health on EQ-5D in
comparison to 24% and 17% for the breast and lung
cancer data sets, respectively. Figure 1b presents the
histograms for each data set and the combined data
set, showing that the distributions differed by data
set, butwithout further information itwasnot possible
to conclude whether this is due to differences in the
severity of the patients in each data set or differences
in the pattern of EQ-5D by condition. The scores for
the QLQ-C30 scales most noticeably varied among
the 3 data sets for physical functioning, role function-
ing, pain, dyspnea, constipation, and global quality of
life.Assessment of the correlations between theEQ-5D
and the QLQ-C30 scale scores indicated that the high-
est correlations are between physical functioning, role
functioning, fatigue, and pain (r = 0.701, r = 0.688, r =
20.625, and r = 20.735, respectively).
YOUNG AND OTHERS
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Mapping Results
Selecting models
Table 2 illustrates the model selection process for
OLS.Model 8 included patient anddisease character-
istics, but these are not statistically significant pre-
dictors of EQ-5D score; therefore, the results for this
model are not shown in Table 2. By definition, all
models predict the overall mean EQ-5D value for
the data set, but underestimate those in near-full or
full health and overestimate those in poorer health
states. No model predicts a value lower than 0.155
(observed values range from20.135 to 1). All models
are able to discriminate between different levels of
health, as measured by categorized EQ-5D value
and ECOG. MAE is large for those in poor health,
which is expected given the range of model predic-
tions. Item-level models consistantly performed
better than the domain and total score models,
although they are most likely to overfit and are poor
at predicting values away from the overall mean for
the data set that is similar to that of other mapping
studies in the literature.14,34 All of the summary sta-
tistics and model performance tests are ranked.
Giving all performance statistics equal weighting
indicates that model 6 (significant FACT-G items) is
the best-performing OLS model for estimating EQ-
5D values from the FACT-G. This process is then
repeated for tobit, 2-part, splining, and responsemap-
ping (see Longworth et al.2 for these results) for the
Table 1 Characteristics of the FACT-G and QLQ-C30 Data Sets
FACT-G Data Set QLQ-C30 Data Sets
(n = 530) All (n = 771) Breast (n = 100) Lung (n = 99) Multiple Myeloma (n = 572)
Mean SD Mean SD Mean SD Mean SD Mean SD
Age, y 59.01 11.92 68.31 9.56 53.9 10.94 62.73 10.5 71.79 5.45
Male, % 51.7 44.1 0.0 48.0 50.0
EQ-5D-3L
EQ-5D utility value 0.721 0.22 0.58 0.342 0.765 0.20 0.742 0.20 0.519 0.36
EQ-5D = 1, % 17.5 10.7 24.0 17.1 7.9
Range of EQ-5D-3L 20.135 to 1 20.594 to 1 20.144 to 1 0.088 to 1 20.594 to 1
FACT-G
Physical 20.16 5.70 — — — — — — — —
Social 22.68 4.77 — — — — — — — —
Emotional 17.50 4.46 — — — — — — — —
Functional 17.58 5.86 — — — — — — — —
Total score 77.92 15.16 — — — — — — — —
EORTC QLQ-C30
Physical functioning — — 64.81 25.59 78.27 19.87 69.76 19.62 61.6 26.5
Role functioning — — 59.14 33.18 72.67 27.68 67.51 26.98 55.33 34.17
Emotional functioning — — 69.71 24.91 73 22.69 76.26 21.47 68.01 25.61
Cognitive functioning — — 76.05 22.74 76.83 22.83 77.27 20.54 75.7 23.11
Social functioning — — 69.13 29.82 72 26.15 73.74 23.82 67.83 31.25
Fatiguez — — 45.42 26.16 39.11 20.86 42.87 23.11 46.97 27.3
Nauseaz — — 9.014 17.87 11 19.85 10.27 16.79 8.45 17.69
Painz — — 40.4 32.99 23 24.25 22.56 23.49 46.53 33.54
Dyspneaz — — 24.73 28.97 16.67 22.47 36.7 30.67 24.07 29.09
Sleep disturbancez — — 32.68 32.6 34 31.06 30.98 28.27 32.75 33.59
Appetite lossz — — 27.37 32.53 19.67 28.46 28.62 32.3 28.5 33.1
Constipationz — — 23.13 30.71 11.67 23.39 22.9 29.98 25.17 31.56
Diarrheaz — — 9.511 19.86 15.67 26.99 11.45 20.29 8.1 18.04
Financial impactz — — 19.76 28.78 23.67 30.45 22.9 28.83 18.53 28.42
Global quality of life — — 52.76 23.18 67.92 18.17 62.12 21.04 48.48 22.75
For FACT-G, higher scores indicate better well-being and quality of life. The EORTCQLQ-C30 dimension score ranges from 0 to 100; higher scores indicate
better functioning and quality of life.
FACT-G, Functional Assessment of Cancer Therapy—General Scale; QLQ-C30, European Organization for Research and Treatment Quality of Life Ques-
tionnaire Core 30.
z Higher scores for symptom scales indicate worse symptoms.
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FACT-G and theQLQ-C30. The best-ranked functions
for each model (OLS, tobit, etc.) are then compared
using the same approach.
Best-fitting models: FACT-G
Table 3 and Figure 2 summarize the best-fitting
OLS, tobit, 2-part modeling, splining, and response-
mapping models for the FACT-G. FACT-G item-level
models give the best model predictions for OLS and
tobit, whereas a significant domain-level model
with square terms is the best model for the 2-part
models (model 4). Only domain levels are fitted for
splining and response mapping, and model 3, which
is the one with significant domains, is the best for
Figure 1 EQ-5D distribution for the (a) Functional Assessment of Cancer Therapy—General Scale (FACT-G) data set; and (b) European
Organization for Research and Treatment Quality of Life Questionnaire Core 30 (QLQ-C30) data sets.
YOUNG AND OTHERS
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both of these models. OLS gives the best estimates of
the overall mean and themean by severity group, and
has 1 of the 2 best ranges of predicted values (the 2-
part model covers the widest range). OLS was the
poorest at predicting the median and had the lowest
shrinkage factor, suggesting it would be the most
likely to overpredict results in other studies applying
the mapping algorithm. The response-mapping
model gave reasonable estimates of the mean and
median, but the poorest MAE among severity groups.
All models failed to predict anyone in perfect health,
underpredicted the top of the EQ-5D scale, and over-
predicted the bottom end of the scale. However, the
overprediction at the lower end of the scale is perhaps
unsurprising given that few responders in the FACT-
G data set reported severe problems. A mean ranking
of models among the different model performance
statistics shows OLS to give the best predictions
(mean ranking = 2.1), followed by tobit (mean =
2.4), with 2-part models and response mapping giv-
ing the poorest predictions (mean = 3.6, mean = 3.5,
respectively). Table 4 presents the regression coeffi-
cients for the best-fitting model (OLS FACT-G signif-
icant items).
Best-fitting models: QLQ-C30
Sevenmodels’ specifications (models 2 to 8;model
1 was excluded because the QLQ-C30 does not have
an overall total score) are fitted for the QLQ-C30.
Table 5 and Figure 2 present the predicted EQ-5D val-
ues for the best-fitting models for each estimation
technique alongside model performance statistics
for the QLQ-C30. As with FACT-G, the item-level
models give the best model predictions for OLS and
tobit models (model 8, including items and sociode-
mographic characteristics). These models are best at
predicting the overall mean EQ-5D value. Item-level
models with sociodemographic characteristics give
the best model performance for 2-part models. The
2-part model resulted in a more accurate prediction
of the median than predictions for OLS, tobit, splin-
ing, and response mapping. The splining model has
the least deviation from the shrinkage coefficient of
1 (model 3). The best-performing response-mapping
model includes all domains with age and gender for
some of the dimensions, and this model has the low-
estMAEs on average. None of themodels predicts the
full range of observed EQ-5D values, with no predic-
tions at the best or worst EQ-5D values. The mean
ranking indicates that the response mapping was
the best-performing model (mean rank = 2.4), with
OLS and tobit also performing well (mean = 2.6,
mean = 2.8, respectively) and splining giving the
poorest overall performance (mean = 3.7). Table 6
presents coefficients for the best-fittingmodel (model
8 response-mapping model).
DISCUSSION
This article reports mapping functions from 2
widely used cancer-specific HRQL measures, the
EORTC QLQ-C30 and the FACT-G, to the EQ-5D.
Generally, OLS and tobit models perform well for
both EORTC QLQ-C30 and FACT-G. However, the
best-performing model for the EORTC QLQ-C30 was
response mapping, whereas OLS gave the best esti-
mates for FACT-Gwith response-mapping producing
poor predictions. The advantage of response map-
ping being the best model for EORTC QLQ-C30 is
that any EQ-5D-3L tariff can be applied to the model.
However, these differences in model type are
unlikely to represent general findings because it is
expected that the best-performing model specifica-
tion and type can vary by measures mapped to and
from, including different EQ-5D-3L country tariffs,
the population, and the data set.
The poor performance of the response-mapping
approach in the FACT-G data set may be due to the
limited number of responders in poor health. This
restricted the response-mapping models we fitted to
those, including FACT-G overall or domain sub-
scores. The low number of responders in poor health
was surprising, because the responders all had stage
III or IV cancer and covered a range of different can-
cers, but it might be due to the FACT-G study asking
respondents to fill in a large number of question-
naires. In addition to the ones reported here, respond-
ers completed EQ-5D-5L, disease-specific FACT-G
modules, and 2 further psychometric questionnaires,
making the task quite lengthy and thus potentially
biasing the sample to more healthy respondents.
The limited range of the FACT-G scores in the estima-
tion data set means that the FACT-G mapping results
are not necessarily generalizable to other studies,
unless applied to a population in mild to moderate
health.
The FACT-G sample size may also have added to
the poor performance of response mapping. With
a larger sample (e.g., 2000 respondents), you would
obtain more accurate predictions of those in level 3,
because although the percentage of observations
for this level might remain the same (e.g., 3%)
the number of observations from which estimates
could be made would increase, giving more reliable
estimates. Further work is needed on sample size
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recommendations for the more complex models,
such as response mapping.
Other common mapping models are CLAD and
GLM. Like the tobit model, the CLAD model also
deals with the censored nature of the data and produ-
ces consistent estimates in the presence of heterosce-
dasticity and nonnormality,35,36 but it is a median-
based model rather than a mean-based model, and
there is some debate regarding its suitability for esti-
mating utility values in economic evaluation.37,38
Therefore, this model was not fitted here. Generalized
linear models (GLMs) were not fitted either because
initial GLM models gave similar results to OLS.
A number of mapping functions have been
published in the literature for EORTC QLQ-
C30.5,6,8–11,14 These published studies did not
explore the full range of possible mapping functions,
as has been done here. Proskorovsky et al.7 estimated
a mapping function from the samemultiple myeloma
data set used in this study but, similar to other stud-
ies, only reported using OLS. The results here are
also based on pooled data from 3 data sets for 3 differ-
ent types of cancer to produce reliable mapping esti-
mates from a large sample. Pooling 3 types of cancer
has increased the generalizability of the results rather
than focusing on 1 specific type of cancer. Further-
more, a recent study by Arnold et al.39 examined
the external validity of published mapping func-
tions from QLQ-C30 to EQ-5D and included the
response-mapping function presented in this arti-
cle. They found that our mapping function per-
formed better than other published mapping
functions in predicting EQ-5D.2,5,6,7,10,12,15,16 For
FACT-G, only 1 published mapping function exists
in which the authors acknowledged that estimates
were unreliable.4
Table 4 Coefficients for the Best-Fitting Mapping Model From FACT-G: OLS Model 6
Domain Item Item Level OLS Model 6
Physical Lack of energy Very much (baseline level)
Quite a bit 0.045
Somewhat 0.036
A little bit 0.071
Not at all 0.118
Trouble meeting need of family Very much (baseline level)
Quite a bit 20.028
Somewhat 0.049
A little bit 0.088
Not at all 0.098
Pain Very much (baseline level)
Quite a bit 0.125
Somewhat 0.219
A little bit 0.240
Not at all 0.342
Emotional I feel sad Very much (baseline level)
Quite a bit 20.085
Somewhat 20.019
A little bit 20.006
Not at all 20.004
Losing hope Very much (baseline level)
Quite a bit 20.081
Somewhat 20.007
A little bit 0.013
Not at all 0.060
Functional Able to work Not at all (baseline level)
A little bit 0.113
Somewhat 0.130
Quite a bit 0.150
Very much 0.152
Constant 20.597
FACT-G, Functional Assessment of Cancer Therapy—General Scale; OLS, ordinary least squares.
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It is evident from the literature that studies report
different model fit and selection criteria, with some
focusing on model goodness of fit and others on the
predictive ability of the model. Mapping models
should be selected based on their predictive abil-
ity;25,40 however, within this, there are still a number
of criteria from which a model can be selected, and
different choices can result in alternative models
being selected. For example, if the accuracy in pre-
dicting EQ-5D values based on mean values by sever-
ity groups was chosen as the key criterion, then the
tobit model would be preferred to the OLS model in
Figure 2 Observed and predicted EQ-5D values for the best-performing models for the (a) Functional Assessment of Cancer Therapy—-
General Scale (FACT-G) data set; and (b) European Organization for Research and Treatment Quality of Life Questionnaire Core 30 (QLQ-
C30) data sets.
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the FACT-Gmodels. If focus was on the overall mean
for the QLQ-C30models, then the OLSmodels would
be preferred. In this article, we have given equal
weighting to all model-fitting criteria and have used
this to generate a ranking of each model. The ranking
criteriausedheredonot take account of themagnitude
of the performance statistic and how accurate these
are, and further research is needed to explore whether
it is possible to account for thiswhen selectingmodels
and to produce more detailed guidelines on selecting
appropriate mapping models.
The OLS models perform reasonably well in pre-
dicting EQ-5D values fromboth cancer-specificmeas-
ures, and response mapping performs the best for the
QLQ-C30 data set. We recommend that both types of
models are considered for future mapping studies,
but note that the responsemapping is likely to require
a broad spectrum of EQ-5D responses to produce
a reliable mapping function and potentially a large
number of responses. Both preferred models pre-
sented here could be used to predict EQ-5D values
in studies that include similar patients; however,
the generalizability of the FACT-G mapping function
is limited to predictions for respondents in mild and
moderate health states.We also recommend transpar-
ency in reporting the criteria that are used to select
mapping functions that are recommended for use
and whether equal weighting is used.
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